BLB&B Advisors LLC Has $12.11 Million Position in Zoetis Inc. (NYSE:ZTS)

BLB&B Advisors LLC decreased its position in shares of Zoetis Inc. (NYSE:ZTS) by 3.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 74,331 shares of the company’s stock after selling 2,985 shares during the period. BLB&B Advisors LLC’s holdings in Zoetis were worth $12,111,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in ZTS. Cherry Creek Investment Advisors Inc. boosted its holdings in Zoetis by 2.0% in the third quarter. Cherry Creek Investment Advisors Inc. now owns 3,021 shares of the company’s stock worth $590,000 after acquiring an additional 58 shares in the last quarter. Grove Bank & Trust raised its position in shares of Zoetis by 0.5% during the third quarter. Grove Bank & Trust now owns 11,763 shares of the company’s stock worth $2,298,000 after purchasing an additional 61 shares during the period. Hancock Whitney Corp lifted its holdings in shares of Zoetis by 0.3% in the 3rd quarter. Hancock Whitney Corp now owns 18,569 shares of the company’s stock worth $3,628,000 after purchasing an additional 61 shares in the last quarter. Strategy Asset Managers LLC grew its position in Zoetis by 3.5% in the 3rd quarter. Strategy Asset Managers LLC now owns 1,822 shares of the company’s stock valued at $356,000 after purchasing an additional 62 shares during the period. Finally, Procyon Advisors LLC increased its stake in Zoetis by 1.4% during the 4th quarter. Procyon Advisors LLC now owns 4,712 shares of the company’s stock valued at $768,000 after purchasing an additional 63 shares in the last quarter. 92.80% of the stock is owned by institutional investors.

Zoetis Stock Down 1.6 %

ZTS stock opened at $171.37 on Friday. The stock has a market cap of $77.32 billion, a P/E ratio of 32.21, a P/E/G ratio of 2.77 and a beta of 0.90. The company has a current ratio of 3.69, a quick ratio of 2.27 and a debt-to-equity ratio of 1.26. The stock’s fifty day simple moving average is $169.34 and its two-hundred day simple moving average is $179.28. Zoetis Inc. has a 1-year low of $144.80 and a 1-year high of $200.53.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be issued a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.17%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis’s dividend payout ratio (DPR) is currently 37.59%.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on ZTS. Morgan Stanley dropped their price objective on shares of Zoetis from $248.00 to $243.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 29th. JPMorgan Chase & Co. raised their price target on shares of Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a research report on Friday, October 11th. Leerink Partners initiated coverage on Zoetis in a report on Monday, December 2nd. They set an “outperform” rating and a $215.00 price objective for the company. Stifel Nicolaus dropped their target price on Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a report on Tuesday, January 7th. Finally, UBS Group initiated coverage on Zoetis in a report on Monday, December 9th. They set a “neutral” rating and a $196.00 price target for the company. One analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $215.00.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.